Related Experiment Video

Updated: May 11, 2026

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration
11:13

Exploring the Pharmacological Action and Molecular Mechanism of Salidroside in Inhibiting MCF-7 Cell Proliferation and Migration

Published on: June 9, 2023

Salinomycin induces activation of autophagy, mitophagy and affects mitochondrial polarity: differences between

Jaganmohan Reddy Jangamreddy1, Saeid Ghavami, Jerzy Grabarek

  • 1Depart. Clinical and Experimental Medicine (IKE), Division of Cell Biology, Linköping Univ., Sweden.

Biochimica Et Biophysica Acta
|May 4, 2013
PubMed

Insights

Salinomycin triggers a strong, protective autophagy in cancer cells, unlike normal cells. This suggests Salinomycin

Area of Science:

  • Molecular Biology
  • Cell Biology
  • Cancer Research

Background:

  • Salinomycin's cytotoxicity involves Ca(2+), cytochrome c, and caspase activation.
  • Salinomycin may target Wnt/β-catenin signaling to eliminate cancer stem cells.

Purpose of the Study:

  • To investigate the molecular mechanism of Salinomycin's toxicity and preferential action against cancer cells.
  • To elucidate Salinomycin's effect on autophagy, mitochondrial function, and ATP levels in cancer versus normal cells.

Main Methods:

  • Treatment of prostate cancer, breast cancer, and normal dermal fibroblast cell lines with Salinomycin and Rapamycin.
  • Assessment of autophagic response, mitophagy, mitoptosis, mitochondrial membrane potential, and cellular ATP levels.
  • Analysis of Salinomycin's toxicity in the context of the Warburg effect.

Main Results:

  • Salinomycin induced a potent autophagic response in cancer cells, acting as a protective mechanism.
  • Cancer cells exhibited mitophagy, mitoptosis, and increased mitochondrial membrane potential, alongside significant ATP depletion.
  • Normal fibroblasts showed resistance to Salinomycin-induced ATP depletion, despite initial mitochondrial mass decrease.

Conclusions:

  • Salinomycin exhibits preferential toxicity towards cancer cells, mediated by a strong, protective autophagic response.
  • Salinomycin's mechanism involves mitophagy, mitoptosis, and ATP depletion, with potential for combination therapy with autophagy inhibitors like Chloroquine.
  • The findings offer insights into Salinomycin's clinical application, particularly in conjunction with its differential effects on cancer versus normal cells.

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Destabilization of Microtubules01:45

Destabilization of Microtubules

The destabilization of microtubules can occur during different stages of the microtubule lifecycle, such as nucleation or elongation. It can take place at either end of the microtubule or in the microtubule lattices as a whole. The lifespan of individual microtubules within a cell varies according to the cell type and stage of the cell cycle. During interphase, the lifespan of the microtubule is about 30 minutes, while during cell division, it is about 15 minutes. In axonal microtubules of...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...